Drug Trial Radar · NCT03486873
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,500
Planned (sponsor's estimate)
Start
Aug 21, 2018
Primary completion
Aug 4, 2043
Study completion Aug 4, 2043
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Apr 3, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will transition to this extension study in one of the following three phases, depending on the study phase they were in at the completion of the parent study. Participants who were in the First Course Phase of study treatment with pembrolizumab or lenvatinib in their parent study will enter the First Course Phase of this study and complete up to 35 doses or more every 3 weeks (Q3W) or 17 doses or more every 6 weeks (Q6W) of study treatment with pembrolizumab or a pembrolizumab-based combination or lenvatinib according to arm assignment. Participants who were in the Follow-up Phase in the parent study (post-treatment or Survival Follow-up Phase) will enter the Survival Follow-up Phase of this study. Participants who were in the Second Course Phase in their parent study will enter Second Course Phase of this study and complete up to 17 doses Q3W or 8 doses Q6W of study treatment with pembrolizumab or a pembrolizumab-based combination according to arm assignment. Any participant originating from a parent trial where crossover to pembrolizumab was permitted upon disease progression may be eligible for 35 doses as Q3W or 17 doses Q6W of pembrolizumab (approximately 2 years), if they progress while on the control arm and pembrolizumab is approved for the indication in the country where the potential eligible crossover participant is being evaluated.
Conditions
- Solid Tumors
- Hematologic Malignancies
Interventions
PembrolizumabDrug
200 or 400 mg IV infusion
Standard of Care (SOC)Drug
IV infusion or oral tablets
LenvatinibDrug
Oral capsules
OlaparibDrug
300mg or 250mg or 100mg oral tablers
MK-4280Drug
IV Infusion
MK-4280ABiological
800mg favezelimab + 200mg pembrolizumab IV Infusion
Pembrolizumab (+) Berahyaluronidase alfaBiological
395 mg or 790 mg SC administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to approximately 10 years
Locations
782 sites in 51 countries. Site status is shown where the registry gives one.
Arizona Cancer Center at UMC North ( Site 0018)
Tucson, Arizona · Recruiting
Comprehensive Blood & Cancer Center [Bakersfield, CA] ( Site 0054)
Bakersfield, California · Recruiting
California Cancer Associates for Research & Excellence ( Site 0016)
Fresno, California · Completed
Providence Medical Foundation ( Site 0087)
Fullerton, California · Completed
The Angeles Clinic and Research Institute ( Site 0005)
Los Angeles, California · Active not recruiting
UCLA - Hematology/Oncology - Administrative Office ( Site 0009)
Los Angeles, California · Recruiting
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0076)
Orange, California · Completed
Stanford Cancer Center ( Site 0086)
Palo Alto, California · Recruiting
UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0004)
San Francisco, California · Recruiting
Providence Saint John's Health Center ( Site 0059)
Santa Monica, California · Recruiting
University of Colorado Cancer Center ( Site 0021)
Aurora, Colorado · Recruiting
Yale Cancer Center ( Site 0014)
New Haven, Connecticut · Completed
Georgetown University Medical Center ( Site 0023)
Washington D.C., District of Columbia · Active not recruiting
Holy Cross Hospital, Michael & Dianne Bienes Comp Cancer Ctr ( Site 0022)
Fort Lauderdale, Florida · Recruiting
Baptist MD Anderson Cancer Center ( Site 0083)
Jacksonville, Florida · Completed
Mount Sinai Braman Comprehensive Cancer Center ( Site 0031)
Miami Beach, Florida · Recruiting
Moffitt Cancer Center ( Site 0011)
Tampa, Florida · Completed
Emory School of Medicine ( Site 0013)
Atlanta, Georgia · Completed
Augusta University ( Site 0077)
Augusta, Georgia · Completed
Northwest Georgia Oncology Centers PC ( Site 0061)
Marietta, Georgia · Recruiting
Kaiser Permanente Moanalua Medical Center ( Site 0063)
Honolulu, Hawaii · Completed
The University of Chicago ( Site 0020)
Chicago, Illinois · Recruiting
University of Iowa Hospital and Clinics ( Site 0026)
Iowa City, Iowa · Recruiting
James Graham Brown Cancer Center ( Site 0058)
Louisville, Kentucky · Recruiting
Mercy Health-Paducah Cancer Center ( Site 0084)
Paducah, Kentucky · Recruiting
Women's Cancer Care ( Site 0088)
Covington, Louisiana · Recruiting
MedStar Franklin Square Medical Center ( Site 0046)
Baltimore, Maryland · Recruiting
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 0056)
Baltimore, Maryland · Recruiting
Maryland Oncology Hematology (MOH) ( Site 8000)
Columbia, Maryland · Recruiting
Massachusetts General Hospital ( Site 0041)
Boston, Massachusetts · Active not recruiting
Dana-Farber Cancer Institute ( Site 0006)
Boston, Massachusetts · Active not recruiting
Karmanos Cancer Institute ( Site 0047)
Detroit, Michigan · Recruiting
Mayo Clinic in Rochester, Minnesota ( Site 0002)
Rochester, Minnesota · Active not recruiting
Comprehensive Cancer Centers of Nevada ( Site 0043)
Las Vegas, Nevada · Recruiting
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0038)
Hackensack, New Jersey · Active not recruiting
Cancer Institute of New Jersey ( Site 0025)
New Brunswick, New Jersey · Recruiting
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0032)
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center ( Site 0012)
New York, New York · Completed
White Plains Hospital-Center for Cancer Care ( Site 0069)
White Plains, New York · Recruiting
WakeMed Cancer Care - Waverly Hematology & Medical Oncology ( Site 0074)
Cary, North Carolina · Active not recruiting
Showing 40 of 782 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.